Elexacaftor/Tezacaftor/Ivacaftor — Membership Pricing

Other medications in Respiratory & Allergies

• Fluticasone Nasal
• Formoterol
• Guaifenesin
• Hydroxyzine
• Ivacaftor
• Levalbuterol
• Levocetirizine
• Lumacaftor-Ivacaftor

About Elexacaftor-Tezacaftor-Ivacaftor

Elexacaftor tezacaftor ivacaftor represents a significant advancement in treating cystic fibrosis, offering hope for many patients. However, its high cost can be a major barrier. TheDrugClub is dedicated to helping members navigate these expenses, providing pathways to potential savings and making vital medications like this more accessible through our membership program.

Elexacaftor Tezacaftor Ivacaftor: A Breakthrough in Cystic Fibrosis Treatment

Cystic Fibrosis (CF) is a complex, progressive genetic disease that causes persistent lung infections and limits the ability to breathe over time. For individuals living with CF, every advancement in treatment offers a beacon of hope. Elexacaftor tezacaftor ivacaftor is one such groundbreaking medication, offering a new lease on life for many.

What Does It Treat?

Elexacaftor tezacaftor ivacaftor is approved for the treatment of cystic fibrosis in patients aged 2 years and older who have at least one copy of the *F508del* mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. This specific genetic mutation is one of the most common causes of CF, and this medication targets the underlying defect, rather than just the symptoms.

How Does It Work?

This medication is a combination of three active ingredients, collectively known as a CFTR modulator. The *F508del* mutation leads to a defective CFTR protein that doesn't fold correctly and isn't transported to the cell surface, or if it does, it doesn't function properly. Elexacaftor and tezacaftor are 'correctors' that help the defective CFTR protein fold properly and move to the cell surface. Ivacaftor is a 'potentiator' that helps the corrected CFTR protein open more frequently once it reaches the cell surface, allowing chloride ions to flow through. This improved ion flow helps to thin mucus in the lungs and other organs, reducing the severity of CF symptoms and progression.

Understanding the Costs

As a highly specialized and innovative medication, elexacaftor tezacaftor ivacaftor carries a significant price tag. The typical list price for this medication can often run into hundreds of thousands of dollars per year, making it one of the most expensive drugs on the market. This cost can be a substantial burden for patients and their families, even with insurance.

How TheDrugClub Helps Members Save

At TheDrugClub, we understand the financial challenges associated with life-changing medications like elexacaftor tezacaftor ivacaftor. While TheDrugClub is not an insurance provider, our membership program is designed to help you access potential savings. Members may receive active-formulary benefits or discount pricing through various channels available via our program. This means that depending on your specific health plan and our partnerships, you could see a reduction in your out-of-pocket expenses.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Elexacaftor/Tezacaftor/Ivacaftor is approved for (FDA label)

TRIKAFTA is indicated for the treatment of cystic fibrosis (CF) in adult and pediatric patients aged 2 years and older who have a clinical diagnosis of CF and who have at least one variant in the cystic fibrosis transmembrane conductance regulator ( CFTR ) gene that is either responsive based on clinical and/or in vitro data (see Table 6 ) or results in production of CFTR protein [see Clinical Pharmacology (12.1) ] . If the patient's genotype is unknown, an FDA-cleared CF genetic test should be used to confirm the presence of at least one variant in the CFTR gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein.

Source: Read the full FDA label on DailyMed. Label effective date: June 22, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Elexacaftor/Tezacaftor/Ivacaftor (FDA label)

WARNING: DRUG-INDUCED LIVER INJURY AND LIVER FAILURE TRIKAFTA can cause serious and potentially fatal drug-induced liver injury. Cases of liver failure leading to transplantation and death have been reported in patients with and without a history of liver disease taking TRIKAFTA, in both clinical trials and the postmarketing setting [see Adverse Reactions (6) ]. Liver injury has been reported within the first month of therapy and up to 15 months following initiation of TRIKAFTA . Assess liver function tests (ALT, AST, alkaline phosphatase, and bilirubin) in all patients prior to initiating TRIKAFTA. Assess liver function tests every month during the first 6 months of treatment, then every 3 months for the next 12 months, then at least annually thereafter. Consider more frequent monitoring for patients with a history of liver disease or liver function test elevations at baseline [see Dosage and Administration (2.1) , Warnings and Precautions (5.1) , Adverse Reactions (6) and Use in Specific Populations (8.7) ] . Interrupt TRIKAFTA for significant elevations in liver function tests or in the event of signs or symptoms of liver injury. Consider referral to a hepatologist. Follow patients closely with clinical and laboratory monitoring until abnormalities resolve. If abnormalities resolve, resume treatment only if the benefit is expected to outweigh the risk. Closer monitoring is advised after resuming TRIKAFTA [see Warnings and Precautions (5.1) ] . TRIKAFTA should not be used in patients with severe hepatic impairment (Child-Pugh Class C).

Source: FDA prescribing information (DailyMed). Set ID: f354423a-85c2-41c3-a9db-0f3aee135d8d. SPL document ID: b63ac090-8d8b-43a0-82d1-558127f2d598. Label effective date: June 22, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Elexacaftor/Tezacaftor/Ivacaftor (FDA label)

Tablets: Fixed-dose combination containing elexacaftor 50 mg, tezacaftor 25 mg and ivacaftor 37.5 mg co-packaged with ivacaftor 75 mg; Fixed-dose combination containing elexacaftor 100 mg, tezacaftor 50 mg, and ivacaftor 75 mg co-packaged with ivacaftor 150 mg. ( 3 ) Oral granules: Unit-dose packets of elexacaftor 100 mg, tezacaftor 50 mg and ivacaftor 75 mg co-packaged with unit-dose packets of ivacaftor 75 mg; Unit-dose packets of elexacaftor 80 mg, tezacaftor 40 mg and ivacaftor 60 mg co-packaged with unit-dose packets of ivacaftor 59.5 mg. ( 3 ) Tablets : Fixed-dose combination containing elexacaftor 50 mg, tezacaftor 25 mg, and ivacaftor 37.5 mg co-packaged with ivacaftor 75 mg: Elexacaftor, tezacaftor and ivacaftor tablets are light orange, oblong-shaped and debossed with "T50" on one side and plain on the other Ivacaftor tablets are light blue, oblong-shaped, and printed with "V 75" in black ink on one side and plain on the other Fixed-dose combination containing elexacaftor 100 mg, tezacaftor 50 mg, and ivacaftor 75 mg co-packaged with ivacaftor 150 mg: Elexacaftor, tezacaftor and ivacaftor tablets are orange, oblong-shaped and debossed with "T100" on one side and plain on the other Ivacaftor tablets are light blue, oblong-shaped, and printed with "V 150" in black ink on one side and plain on the other Oral Granules : Fixed-dose combination oral granules containing elexacaftor 100 mg, tezacaftor 50 mg, and ivacaftor 75 mg co-packaged with ivacaftor 75 mg oral granules: Elexacaftor, tezacaftor, and ivacaftor oral granules are white to off-white, sweetened, unflavored granules approximately 2 mm in diameter contained in a white and orange unit-dose packet Ivacaftor oral granules are white to off-white, sweetened, unflavored granules approximately 2 mm in diameter contained in a white and pink unit-dose packet Fixed-dose combination oral granules containing elexacaftor 80 mg, tezacaftor 40 mg, and ivacaftor 60 mg co-packaged with ivacaftor 59.5 mg oral granules: Elexacaftor, tezacaftor, and ivacaftor oral granules are white to off-white, sweetened, unflavored granules approximately 2 mm in diameter contained in a white and blue unit-dose packet Ivacaftor oral granules are white to off-white, sweetened, unflavored granules approximately 2 mm in diameter contained in a white and green unit-dose packet

Source: FDA prescribing information (DailyMed). Set ID: f354423a-85c2-41c3-a9db-0f3aee135d8d. SPL document ID: b63ac090-8d8b-43a0-82d1-558127f2d598. Label effective date: June 22, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Elexacaftor/Tezacaftor/Ivacaftor (FDA label)

The following clinically significant adverse reactions are discussed in greater detail in other sections of the labeling: Drug-Induced Liver Injury and Liver Failure [see Warnings and Precautions (5.1) ] Hypersensitivity Reactions, Including Anaphylaxis [see Warnings and Precautions (5.2) ] Intracranial Hypertension [see Warnings and Precautions (5.3) ] Neuropsychiatric Events, Including Suicidal Thoughts and Behaviors [see Warnings and Precautions (5.4) ] Cataracts [see Warnings and Precautions (5.7) ] The most common adverse drug reactions to TRIKAFTA (≥5% of patients and at a frequency higher than placebo by ≥1%) were headache, upper respiratory tract infection, abdominal pain, diarrhea, rash, alanine aminotransferase increased, nasal congestion, blood creatine phosphokinase increased, aspartate aminotransferase increased, rhinorrhea, rhinitis, influenza, sinusitis, blood bilirubin increased and constipation. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Vertex Pharmaceuticals Incorporated at 1-877-634-8789 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Source: FDA prescribing information (DailyMed). Set ID: f354423a-85c2-41c3-a9db-0f3aee135d8d. SPL document ID: b63ac090-8d8b-43a0-82d1-558127f2d598. Label effective date: June 22, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Elexacaftor/Tezacaftor/Ivacaftor (FDA label)

None. None. ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: f354423a-85c2-41c3-a9db-0f3aee135d8d. SPL document ID: b63ac090-8d8b-43a0-82d1-558127f2d598. Label effective date: June 22, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Elexacaftor/Tezacaftor/Ivacaftor (FDA label)

Drug-induced liver injury and liver failure : TRIKAFTA can cause serious and potentially fatal drug-induced liver injury. Assess liver function tests (ALT, AST, alkaline phosphatase, bilirubin) in all patients prior to initiating and throughout treatment with TRIKAFTA. Interrupt TRIKAFTA in the event of significant elevations in liver function tests or signs or symptoms of liver injury. TRIKAFTA should not be used in patients with severe hepatic impairment (Child-Pugh Class C). TRIKAFTA is not recommended in patients with moderate hepatic impairment (Child-Pugh Class B). ( 2.1 , 2.3 , 5.1 , 6 , 8.7 , 12.3 ) Hypersensitivity reactions : Angioedema and anaphylaxis have been reported with TRIKAFTA in the postmarketing setting.

Source: FDA prescribing information (DailyMed). Set ID: f354423a-85c2-41c3-a9db-0f3aee135d8d. SPL document ID: b63ac090-8d8b-43a0-82d1-558127f2d598. Label effective date: June 22, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Elexacaftor/Tezacaftor/Ivacaftor (FDA label)

Strong CYP3A inducers: Avoid concomitant use. ( 5.5 , 7.1 , 12.3 ) Strong or moderate CYP3A inhibitors: Reduce TRIKAFTA dosage when used concomitantly. Avoid food or drink containing grapefruit. ( 2.4 , 5.6 , 7.1 , 12.3 ) 7.1 Effect of Other Drugs and Grapefruit on TRIKAFTA Strong CYP3A Inducers Concomitant use of TRIKAFTA with strong CYP3A inducers is not recommended. Elexacaftor, tezacaftor and ivacaftor are substrates of CYP3A (ivacaftor is a sensitive substrate of CYP3A).

Source: FDA prescribing information (DailyMed). Set ID: f354423a-85c2-41c3-a9db-0f3aee135d8d. SPL document ID: b63ac090-8d8b-43a0-82d1-558127f2d598. Label effective date: June 22, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.